Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

Published Date: 01 Aug 2026

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Read Full News

Latest News

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

New Data Put ADCs on the Map in Relapsed SCLC

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

Pelvic RT Tied to Longer Survival in Cervical Cancer

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

Real-World Liso-Cel Results in MCL Consistent With Trials

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

Todays Updates

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

Todays Updates

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

Latest News

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

News All Time

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Recommended News For You

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

More People Than Previously Believed Have Schizophrenia.

Since 2000, the outlook for multiple myeloma has improved.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

Study opens up possibility of bespoke prostate cancer treatment

The American College of Physicians updated its recommendations for colorectal cancer screening.

Recommended Articles For You

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment 

Exploring Innovative Solutions for Infantile Hemangioma Treatment 

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025 

Personalized Cancer Vaccines: The Next Frontier in Precision Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What is Mohs micrographic surgery? 8 FAQs about Mohs

2.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

3.

In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.

4.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

5.

How the skin cancer virus outperforms the replication of host cells.

1.

CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights

2.

AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence

3.

Vaccines that can help prevent cancer

4.

Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment

5.

Quality of Life Through Maintaining Functional Independence During Chronic Hematologic Conditions

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Oropharyngeal Cancer in Relation to HPV Status

2.

Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment

3.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

4.

Efficient Management of First line ALK-rearranged NSCLC - Part V

5.

Managing Common Side Effects During Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot